Biocon Ltd (BIOCON) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Biocon Ltd on NSE and BSE, with an AI summary of each filing.
Press Release
Press Release · 29 Oct 2026, 2:15 pm
Biocon Ranked Among Top 20 Global Biotech and Pharma Employers for 2026 Biocon Limited announced on 29th Oct'26 that it ranked No. 13 among the Top 20 Global Employers in biotechnology, biopharmaceuticals, and pharmaceuticals by U.S.-based Science magazine. This marks the company's 15th consecutive year featured on the list since its debut in 2012. The 2026 survey of ~5,100 participants recognized Biocon for social responsibility, employee respect, and values alignment. Biocon operates across 120+ countries with a workforce of over 9,500 employees, supported by seven manufacturing and three R&D sites globally.
Earnings Conference Call for Analysts and Investors
Intimation · 04 Nov 2026, 4:00 pm
Biocon Schedules Board Meeting and Q2 FY27 Earnings Conference Call Biocon Limited announced its Board of Directors will meet on 4th Nov'26 to approve un-audited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. The company will host an earnings conference call for analysts and investors on 4th Nov'26 at 16:00 hrs IST. The insider trading window remains closed from 1st Oct'26 through 6th Nov'26, reopening on 7th Nov'26. Audio recordings will be available within 24 hours, video recordings within 48 hours, and transcripts within five working days post-call.
Biocon Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve To approve and take on record the un-audited ....
Intimation · 04 Nov 2026, 5:30 am
Biocon Schedules Board Meeting and Q2 FY27 Earnings Call for 4th Nov'26 Biocon Limited announced its Board of Directors will meet on 4th Nov'26 to consider and approve un-audited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. Following the announcement, the company will host its Q2 FY27 earnings conference call on 4th Nov'26 at 16:00 hrs IST. In compliance with insider trading regulations, the trading window for company securities remains closed from 1st Oct'26 to 6th Nov'26, reopening on 7th Nov'26.
BIOCON LIMITED has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 04 Nov 2026, 5:30 am
Biocon Limited has informed the Exchange about Schedule of meet
Intimation · 04 Nov 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 04 Nov 2026, 5:30 am
Company Statement
Others (Uncategorized) · 26 Oct 2026, 1:57 pm
Biocon Secures Global Market Entry for Biosimilar Yesintek Through Janssen Licensing Agreement Biocon Limited has entered into a licensing agreement with Janssen Sciences Ireland, enabling immediate commercialization rights for Yesintek (a proposed biosimilar to Ustekinumab / Stelara) across Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea, and Kazakhstan, subject to regulatory approvals. This expands upon prior agreements covering the US, Europe, UK, Canada, and Japan. Yesintek targets autoimmune indications including Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. Reference drug Stelara recorded global sales of $6.08 billion in 2025.
Company Statement
Others (Uncategorized) · 14 Oct 2026, 1:55 pm
Biocon Secures Earliest Global Launch Dates for Biosimilar Pertuzumab via Genentech Settlement Biocon Limited has entered into a global settlement and licensing agreement with Genentech to resolve all pending patent disputes across the U.S., Canada, and other jurisdictions. The agreement secures earliest licensed launch dates for Pebrilzo, a biosimilar referencing Perjeta (Pertuzumab) for HER2-positive breast cancer. Biocon is licensed to launch Pebrilzo in the EU and UK in Q1 CY'27, the U.S. in Q3 CY'28, and Rest of the World markets across CY'26–CY'28, subject to regulatory approvals. Other financial terms remain confidential.
Disclosure pursuant to Regulation 30 of SEBI Listing Regulations
Others (Uncategorized) · 10 Oct 2026, 8:36 pm
Biocon Receives GST Demand and Penalty Order for FY23 Biocon Limited received an Order-in-Original on 9th Oct'26 from Andhra Pradesh GST authorities confirming a total tax demand of ₹1,85,28,762, interest of ₹1,17,59,033, and a penalty of ₹18,52,476 for FY22-23. The order cites non-submission of SEZ endorsement documents, incorrect input tax credit reversals, and improper Input Service Distribution claims. Biocon stated the order has no material operational or financial impact and intends to contest the demand by filing a rectification application or appeal.
Grant of Employee Stock Options
Others (Uncategorized) · 02 Oct 2026, 3:09 am
Biocon Grants 94.6 Lakh Stock Options Under Long-Term Incentive Plan Biocon granted 94,60,232 stock options to eligible employees under the Biocon Unity Long Term Incentive Plan 2026, effective 1st Oct'26. The grant covers 94,60,232 equity shares of face value Rs. 5 each, with an exercise price set at Rs. 5 per option. Options are exercisable within 12 months from their respective vesting dates and will be implemented via the Biocon India Limited Employees Welfare Trust through direct allotment or secondary acquisition. Shares allotted upon exercise will rank pari passu with existing equity.
Company Secretary
Others (Uncategorized) · 25 Sept 2026, 2:03 pm
Biocon Malaysia Secures UK MHRA Approval for Semglee Fill-Finish Unit Biocon Limited announced on 25th Sep'26 that its Malaysian insulin manufacturing facility received UK MHRA approval for its new drug product fill-finish unit for Semglee (insulin glargine). This follows an earlier regulatory clearance obtained from the European Medicines Agency (EMA) in Jul'26 for the same fill-finish line, strengthening the company's global supply capabilities for European and UK markets.
Press Release
Press Release · 21 Sept 2026, 1:58 pm
Biocon Biologics Secures Positive EMA CHMP Opinion for Pertuzumab Biosimilar Biocon Biologics, a wholly owned subsidiary of Biocon Limited, received a positive opinion from the EMA's CHMP on 21st Sep'26 recommending marketing authorization for Pebrilzo (Pertuzumab biosimilar, 420 mg concentrate solution for infusion). The drug targets HER2-positive breast cancer across early, adjuvant, and metastatic stages. Notably, Pebrilzo is the first monoclonal antibody biosimilar recommended under the EMA's tailored clinical development approach based on analytical and pharmacokinetic data. Final European Commission marketing approval remains pending.
Communication regarding remittance of final dividend for the FY 2025-26
Dividend · 09 Sept 2026, 7:32 pm
Biocon Remits Final Dividend for FY 2025-26 Biocon Limited has communicated the electronic remittance of its final dividend for FY 2025-26. Shareholders approved a dividend of ₹0.50 per equity share (face value ₹5 each) at the 48th Annual General Meeting held on 6th Aug'26. The payout corresponds to holdings as of the record date, 3rd Jul'26. Communications have been dispatched to shareholders without registered email addresses, directing any unreceived credit queries to KFin Technologies Limited, the company's Registrar and Share Transfer Agent.
Intimation of Schedule of Meetings with Analyst(s)/Institutional Investor(s)
Intimation · 08 Sept 2026, 9:33 pm
Biocon Schedules In-Person Investor Roadshow in Mumbai Biocon Limited announced that its management is scheduled to participate in an Investor Roadshow on 11th Sep'26 in Mumbai. The engagement will feature in-person 1x1 and group interactions with analysts and institutional investors. The company confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed during these interactions.
Press Release
Press Release · 08 Sept 2026, 2:01 pm
Biocon Consortium Wins 10-Year Exclusive Pertuzumab Supply Contract in Brazil Biocon Limited announced on 8th Sep'26 that its consortium with Bahiafarma and Bionovis secured a 100% allocation under Brazil's 10-year Productive Development Partnership (PDP) program for Pertuzumab, a HER2-positive breast cancer therapy. The partnership grants exclusive access to Brazil’s public healthcare system, representing ~70% of the nation's demand for the drug. Biocon will receive milestone payments and revenue share over the 10-year period, with the product undergoing phased local manufacturing in Brazil over the mid-to-long term.
Intimation of Schedule of Meetings with Analyst(s)/Institutional Investor(s)
Intimation · 31 Aug 2026, 11:32 pm
Biocon Management to Attend Nomura Investor Conference Biocon's management is scheduled for a virtual group meeting with analysts and institutional investors on 04-Sep-26. The company will participate in the Nomura Asian Credit Corporate Day 2026. Biocon has stated that no Unpublished Price Sensitive Information (UPSI) will be disclosed during the interaction. The schedule is subject to change based on exigencies.
Communication regarding remittance of final dividend for the FY 2025-26
Dividend · 29 Aug 2026, 2:28 am
Biocon Announces Remittance of Final Dividend for FY26 Biocon has announced the remittance of its final dividend for FY26. The dividend of ₹0.50 per equity share (face value ₹5/-) was approved at the AGM on 06 Aug'26. The record date for the dividend was 03 Jul'26. The company began remitting the dividend amount to eligible shareholders via electronic mode on 28 Aug'26. This communication confirms the execution of the previously approved dividend payout for the financial year 2025-26.
The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mylan Inc.
Acquisition/ Disposal of Shares · 26 Aug 2026, 8:21 pm
Mylan Inc. Clarifies Complete Exit from Biocon Mylan Inc. filed a clarification on 26 Aug'26 regarding its sale of Biocon shares. The company confirmed it sold its entire 5.64% stake, comprising 91.97 million shares, via an open market transaction on 14 Jul'26. A previous disclosure on 15 Jul'26 had incorrectly stated its post-sale holding was 5.64%. This correction confirms Mylan's post-transaction shareholding in Biocon is nil, clarifying its complete exit. All other details of the original disclosure remain unchanged.
Company Statement
Others (Uncategorized) · 25 Aug 2026, 2:00 pm
Biocon Gains Japanese Approval for Pegfilgrastim Biosimilar Biocon's subsidiary, Biocon Biologics Ltd., received marketing approval on 25th Aug'26 from Japan's Ministry of Health, Labour and Welfare (MHLW) for its pegfilgrastim biosimilar. The product, a biosimilar to Amgen's Neulasta®, was developed and manufactured by Biocon. Sandoz K.K. will exclusively promote, sell, and distribute the product in Japan. This approval strengthens Biocon's biosimilar portfolio in the Japanese market and expands its global footprint in providing affordable biologic medications.
Company Statement
Others (Uncategorized) · 18 Aug 2026, 2:12 pm
Biocon Secures US FDA Approval for Yesintek Autoinjector Biocon's US subsidiary received supplemental FDA approval on 18th Aug '26 for Yesintek® (ustekinumab-kfce) single-dose prefilled autoinjectors in 45 mg/0.5 ml and 90 mg/ml formats. This new delivery method enhances treatment options for autoimmune conditions like plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The approval expands Biocon's immunology portfolio in the US, strengthening its position in affordable biosimilars. The original Yesintek biosimilar was approved by the FDA on 29th Nov '24.
Investor Meet
Intimation · 12 Aug 2026, 1:26 am
Biocon Management to Meet Investors at Motilal Oswal Conference Biocon management will meet with analysts and institutional investors at the Motilal Oswal 22nd Annual Global Investor Conference. The in-person meetings, scheduled for 17-Aug-26 in Mumbai, will be conducted on a 1x1 or group basis. The company confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed during these interactions. The schedule is subject to potential changes.
Earning call Transcript for Q1 FY27
Transcript · 12 Aug 2026, 1:19 am
Voting Results and Scrutinizer''s report
Annual General Meeting · 09 Aug 2026, 3:24 am
Biocon AGM Resolutions Approved, Including ESOP and Dividend Biocon announced all resolutions passed at its 48th AGM on 06-Aug'26. Shareholders approved FY26 financial statements and a final dividend of ₹0.50 per share. Key approvals included the re-appointment of director Eric Vivek Mazumdar, appointment of S.R. Batliboi & Associates LLP as statutory auditors, and ratification of cost auditor remuneration. Critically, special resolutions to approve the "Biocon Unity Long Term Incentive Plan 2026" (ESOP) and provide related financial assistance were passed, despite significant institutional opposition to the proposals.
Investor Meet
Intimation · 08 Aug 2026, 2:03 am
Biocon Announces Upcoming Analyst and Investor Meeting Biocon management will meet with analysts and institutional investors on 12 Aug'26 as part of the Emkay Confluence 2026. The engagement will be a virtual group interaction. The company has stated that no Unpublished Price Sensitive Information (UPSI) will be disclosed during the meeting. The schedule is subject to potential changes.
Resignation of Statutory auditors of material subsidiaries of the Company.
Change in Auditor · 07 Aug 2026, 4:45 am
Auditors of Material Subsidiary Biocon Biologics Resign B S R & Co. LLP has resigned as statutory auditors of Biocon's material subsidiary, Biocon Biologics Ltd (BBL), effective 06 Aug'26. The resignation aims to align BBL's auditors with those of the parent company, Biocon Ltd, due to the mandatory rotation of B S R & Co. as auditors for the parent. The firm had completed its audit for the year ended 31 Mar'26 and the limited review for the quarter ended 30 Jun'26 prior to resigning. No other reasons were cited.